Date published: 2025-12-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

Bcr Inhibitors

Bcr inhibitors are a class of chemical compounds that primarily target the Bcr protein, a component of the Bcr-Abl fusion protein found in various signaling pathways within cells. The Bcr (Breakpoint Cluster Region) protein, encoded by the BCR gene, plays a pivotal role in intracellular signaling mechanisms, influencing various cellular processes such as proliferation, differentiation, and apoptosis. Bcr inhibitors are designed to disrupt the normal function of this protein, thereby affecting the downstream signaling pathways in which Bcr is involved. The inhibition of Bcr can lead to a cascade of biochemical events that alter the normal signaling dynamics within the cell, influencing the behavior of key proteins and enzymes. This disruption is significant because Bcr is involved in the regulation of certain kinases, such as the serine/threonine kinase activity associated with the N-terminal portion of the Bcr protein, which is known to regulate cytoskeletal organization and cellular motility. The structure of Bcr inhibitors is often tailored to interact with specific domains of the Bcr protein, such as the PH (Pleckstrin Homology) domain or the coiled-coil domain, which are crucial for its interaction with other cellular proteins and its role in signal transduction. The precise mechanism by which these inhibitors bind to and inhibit Bcr can vary, depending on the chemical structure and the specific binding affinities of the inhibitors. By modulating the activity of Bcr, these inhibitors can impact the phosphorylation status of downstream signaling proteins, leading to altered cellular responses. The study and development of Bcr inhibitors involve detailed molecular modeling, structure-activity relationship (SAR) studies, and extensive biochemical assays to ensure their specificity and efficacy in targeting the desired aspects of Bcr-mediated signaling pathways. The chemical complexity of Bcr inhibitors reflects the intricate nature of the protein-protein interactions they are designed to disrupt, making them a significant focus of research in the field of molecular biology and biochemistry.

Items 11 to 16 of 16 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Tyrene CR4

1110670-40-0sc-296677
sc-296677A
5 mg
50 mg
$101.00
$754.00
(0)

Tyrene CR4 exhibits a distinctive affinity for the Bcr protein, characterized by its ability to form robust π-π stacking interactions and electrostatic contacts. This compound induces a significant alteration in Bcr's conformation, impacting its engagement with various signaling partners. The kinetics of its interaction suggest a rapid initial binding followed by a slower, more stable association, allowing for prolonged modulation of Bcr's functional dynamics. Its unique structural attributes facilitate targeted disruption of key protein interactions, influencing cellular signaling pathways.

Bcr-abl Inhibitor

778270-11-4sc-203836
5 mg
$149.00
1
(0)

Bcr-abl Inhibitor demonstrates a remarkable specificity for the Bcr-abl fusion protein, engaging through unique hydrogen bonding and hydrophobic interactions. This compound effectively stabilizes a particular conformation of Bcr-abl, which disrupts its downstream signaling cascades. The inhibitor's binding kinetics reveal a biphasic pattern, with an initial fast association followed by a gradual stabilization phase, enhancing its efficacy in modulating protein interactions and cellular responses.

Elacridar-d4

143664-11-3 (unlabeled)sc-218297
1 mg
$380.00
(0)

Elacridar-d4 exhibits a distinctive mechanism of action as a Bcr inhibitor, characterized by its ability to form strong π-π stacking interactions with aromatic residues in the target protein. This compound alters the conformational dynamics of Bcr, leading to a significant reduction in its activity. The reaction kinetics indicate a slow dissociation rate, allowing for prolonged engagement with the target, which enhances its overall impact on cellular pathways and protein interactions.

Bafetinib

859212-16-1sc-503249
1 mg
$250.00
1
(0)

Bafetinib inhibits both BCR-ABL and Lyn tyrosine kinases, potentially suppressing the activity of c-Abl.

DCC-2036

1020172-07-9sc-364482
sc-364482A
10 mg
50 mg
$480.00
$1455.00
(0)

DCC-2036 (Rebastinib) is a switch control inhibitor of c-Abl, designed to overcome resistance mutations.

KW 2449

1000669-72-6sc-364518
sc-364518A
10 mg
50 mg
$180.00
$744.00
(0)

KW-2449 inhibits multiple kinases including c-Abl and has shown activity against BCR-ABL T315I mutant cells.